Translation and validation of the Nepean Dyspepsia Index for functional dyspepsia in China

World Journal of Gastroenterology

Volumn 15, Issue 25, 2009, Pages 3173-3177

  Tian, Xiao Ping ^a   Li, Ying ^a   Liang, Fan Rong ^a   Sun, Guo Jie ^b   Yan, Jie ^c   Chang, Xiao Rong ^b   Ma, Ting Ting ^a   Yu, Shu Yuan ^a   Yang, Xu Guang ^a  

^a CHENGDU UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b HUBEI UNIVERSITY OF CHINESE MEDICINE   (China)

^c HUNAN UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Functional dyspepsia; Health related quality of life; Nepean Dyspepsia Index; Questionaires; Validation studies

Indexed keywords

ADULT; ARTICLE; CHECKLIST; CHINESE; CONSTRUCT VALIDITY; CONTENT VALIDITY; DISEASE SEVERITY; DYSPEPSIA; FEMALE; FUNCTIONAL DYSPEPSIA; HUMAN; INSTRUMENT VALIDATION; MAJOR CLINICAL STUDY; MALE; NEPEAN DYSPEPSIA INDEX; QUALITY OF LIFE; RATING SCALE; RELIABILITY; SYMPTOMATOLOGY;

EID: 67651241277     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.15.3173     Document Type: Article

References (30)

1. Piessevaux H, De Winter B, Louis E, Muls V, De Looze D, Pelckmans P, Deltenre M, Urbain D, Tack J. Dyspeptic symptoms in the general population: a factor and cluster analysis of symptom groupings. Neurogastroenterol Motil 2009; 21: 378-388
2. Talley NJ, Silverstein MD, Agréus L, Nyrén O, Sonnenberg A, Holtmann G. AGA technical review: evaluation of dyspepsia. American Gastroenterological Association. Gastroenterology 1998; 114: 582-595
3. Kang XQ, Liu ZW, Xie B, Niu XY, Xiao YY, He C. The incidence of Functional Dyspepsia of parts of citizens in Tianjin. Zhonghua Xiaohua Zazhi 2002; 22: 191-192
4. Talley NJ, Verlinden M, Jones M. Quality of life in functional dyspepsia: responsiveness of the Nepean Dyspepsia Index and development of a new 10-item short form. Aliment Pharmacol Ther 2001; 15: 207-216
5. Monés J, Adan A, Segú JL, López JS, Artés M, Guerrero T. Quality of life in functional dyspepsia. Dig Dis Sci 2002; 47: 20-26
6. El-Serag HB, Talley NJ. Systemic review: the prevalence and clinical course of functional dyspepsia. Aliment Pharmacol Ther 2004; 19: 643-654
7. Holtmann G, Adam B, Haag S, Collet W, Grünewald E, Windeck T. Efficacy of artichoke leaf extract in the treatment of patients with functional dyspepsia: a six-week placebo-controlled, double-blind, multicentre trial. Aliment Pharmacol Ther 2003; 18: 1099-1105
8. Meineche-Schmidt V, Talley NJ, Pap A, Kordecki H, Schmid V, Ohlsson L, Wahlqvist P, Wiklund I, Bolling-Sternevald E. Impact of functional dyspepsia on quality of life and health care consumption after cessation of antisecretory treatment. A multicentre 3-month follow-up study. Scand J Gastroenterol 1999; 34: 566-574
9. Rentz AM, Battista C, Trudeau E, Jones R, Robinson P, Sloan S, Mathur S, Frank L, Revicki DA. Symptom and health-related quality-of-life measures for use in selected gastrointestinal disease studies: a review and synthesis of the literature. Pharmacoeconomics 2001; 19: 349-363
10. Mönkemüller K, Malfertheiner P. Drug treatment of functional dyspepsia. World J Gastroenterol 2006; 12: 2694-2700
11. Madisch A, Miehlke S, Labenz J. Management of functional dyspepsia: Unsolved problems and new perspectives. World J Gastroenterol 2005; 11: 6577-6581
12. Talley NJ, Haque M, Wyeth JW, Stace NH, Tytgat GN, Stanghellini V, Holtmann G, Verlinden M, Jones M. Development of a new dyspepsia impact scale: the Nepean Dyspepsia Index. Aliment Pharmacol Ther 1999; 13: 225-235
13. Hashash JG, Abdul-Baki H, Azar C, Elhajj II, El Zahabi L, Chaar HF, Sharara AI. Clinical trial: a randomized controlled cross-over study of flupenthixol + melitracen in functional dyspepsia. Aliment Pharmacol Ther 2008; 27: 1148-1155
14. Talley NJ, Tack J, Ptak T, Gupta R, Giguère M. Itopride in functional dyspepsia: results of two phase III multicentre, randomised, double-blind, placebo-controlled trials. Gut 2008; 57: 740-746
15. Talley NJ, Verlinden M, Jones M. Can symptoms discriminate among those with delayed or normal gastric emptying in dysmotility-like dyspepsia? Am J Gastroenterol 2001; 96: 1422-1428
16. Cho YK, Choi MG, Kim SH, Lee IS, Kim SW, Chung IS, Lee SY, Choi SC, Seol SY. [The effect of mosapride on quality of life in functional dyspepsia] Korean J Gastroenterol 2004; 43: 160-167
17. Talley NJ, Verlinden M, Jones M. Validity of a new quality of life scale for functional dyspepsia: a United States multicenter trial of the Nepean Dyspepsia Index. Am J Gastroenterol 1999; 94: 2390-2397
18. Boeckxstaens GE, Hirsch DP, Kuiken SD, Heisterkamp SH, Tytgat GN. The proximal stomach and postprandial symptoms in functional dyspeptics. Am J Gastroenterol 2002; 97: 40-48
19. Holtmann G, Talley NJ, Liebregts T, Adam B, Parow C. A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med 2006; 354: 832-840
20. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006; 130: 1377-1390
21. Leplege A, Verdier A. The adaptation of health status measures: methodological aspects of the translation procedure. In: Shumaker SA, Berzon RA, eds. The international sssessment of health-related quality of life: theory, translation, measurement and analysis. Oxford: Rapid Communications, 1995: 93-101
22. Hays RD, Anderson R, Revicki D. Psychometric considerations in evaluating health-related quality of life measures. Qual Life Res 1993; 2: 441-449
23. Halder SL, Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd. Impact of functional gastrointestinal disorders on health-related quality of life: a population-based case-control study. Aliment Pharmacol Ther 2004; 19: 233-242
24. Frankhuisen R, Van Herwaarden MA, Heijkoop R, Baron A, Vermeijden R, Smout AJ, Gooszen HG, Samsom M. Functional dyspepsia and irritable bowel syndrome in patients with achalasia and its association with non-cardiac chest pain and a decreased health-related quality of life. Scand J Gastroenterol 2009; 44: 687-691
25. Hu LT, Bentler PM. Cutoff criteria for fit indexes in covariance structure analysis: conventional criteria versus new alternatives. Struct Equ Modeling 1999; 6: 1-55
26. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473-483
27. Kupcinskas L, Lafolie P, Lignell A, Kiudelis G, Jonaitis L, Adamonis K, Andersen LP, Wadström T. Efficacy of the natural antioxidant astaxanthin in the treatment of functional dyspepsia in patients with or without Helicobacter pylori infection: A prospective, randomized, double blind, and placebo-controlled study. Phytomedicine 2008; 15: 391-399
28. Sararaks S, Azman AB, Low LL, Rugayah B, Aziah AM, Hooi LN, Abdul Razak M, Norhaya MR, Lim KB, Azian AA, Geeta S. Validity and reliability of the SF-36: the Malaysian context. Med J Malaysia 2005; 60: 163-179
29. Moayyedi P, Duffett S, Braunholtz D, Mason S, Richards ID, Dowell AC, Axon AT. The Leeds Dyspepsia Questionnaire: a valid tool for measuring the presence and severity of dyspepsia. Aliment Pharmacol Ther 1998; 12: 1257-1262
30. Browne MW, Cudeck R. Alternative ways of assessing model fit. In: Bollen KA, Long JS, Eds. Testing structural equation models. Beverly Hills: Sage, 1993: 136-162